Schonfeld Strategic Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.7M	Buy	71,767 +26,873	+60%	+$9.14M	0.19%	120
2025 Q4	$17.9M	Buy	44,894 +35,185	+362%	+$15.6M	0.09%	222
2025 Q3	$4.43M	Sell	9,709 -49,048	-83%	-$20M	0.03%	639
2025 Q2	$19.2M	Buy	58,757 +55,675	+1,806%	+$15.4M	0.14%	168
2025 Q1	$832K	Sell	3,082 -123,918	-98%	-$31.8M	0.01%	1361
2024 Q4	$29.9M	Buy	127,000 +99,133	+356%	+$26.1M	0.19%	94
2024 Q3	$7.66M	Sell	27,867 -16,108	-37%	-$4.19M	0.06%	380
2024 Q2	$10.7M	Sell	43,975 -191,631	-81%	-$30.3M	0.08%	329
2024 Q1	$35.2M	Buy	235,606 +233,653	+11,964%	+$39M	0.28%	72
2023 Q4	$374K	Sell	1,953 -40,154	-95%	-$6.84M	﹤0.01%	1370
2023 Q3	$7.46M	Buy	42,107 +39,641	+1,608%	+$7.56M	0.07%	437
2023 Q2	$468K	Sell	2,466 -12,770	-84%	-$2.53M	﹤0.01%	1246
2023 Q1	$3.05M	Buy	+15,236	New	+$3.2M	0.03%	583
2022 Q4	–	Sell	-33,615	Closed	-$6.73M	–	2557
2022 Q3	$6.73M	Buy	+33,615	New	+$6.41M	0.06%	432
2022 Q2	–	Sell	-6,700	Closed	-$1.09M	–	2496
2022 Q1	$1.09M	Buy	+6,700	New	+$1.02M	0.01%	944
2021 Q3	–	Sell	-18,968	Closed	-$3.22M	–	2128
2021 Q2	$3.22M	Buy	18,968 +10,868	+134%	+$1.59M	0.04%	572
2021 Q1	$1.14M	Buy	+8,100	New	+$1.22M	0.02%	840
2019 Q3	–	Sell	-73,600	Closed	-$5.34M	–	1005
2019 Q2	$5.34M	Buy	73,600 +10,900	+17%	+$836K	0.19%	133
2019 Q1	$5.86M	Buy	62,700 +47,700	+318%	+$3.99M	0.2%	133
2018 Q4	$1.09M	Sell	15,000 -51,500	-77%	-$3.96M	0.04%	460
2018 Q3	$5.82M	Hold	66,500	–	–	0.26%	111
2018 Q2	$6.55M	Buy	66,500 +51,500	+343%	+$5.11M	0.36%	78
2018 Q1	$1.79M	Sell	15,000 -3,575	-19%	-$461K	0.13%	218
2017 Q4	$2.36M	Buy	+18,575	New	+$2.33M	0.19%	147
2016 Q4	–	Sell	-25,618	Closed	-$1.74M	–	536
2016 Q3	$1.74M	Buy	+25,618	New	+$1.81M	0.3%	86